ERBB2 and non-small cell lung carcinoma: Furmonertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI) with enhanced hydrophobic properties due to its trifluoroethoxy group, has shown activity against EGFR exon 20 insertions (ex20ins) but has not been explored in HER2-mutant NSCLC.<h4>Case description</h4>A 65-year-old male smoker presented with progressive dyspnea and a performance status (PS) of 2.